PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy
Clinical trial NCT00388336 · COMPLETED
Trial details
- NCT number
- NCT00388336
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2004-02-01
- Enrollment
- 57
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.